• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Searching gene to manufacture the companion diagnostic agent targeting the HB-EGF.

Research Project

Project/Area Number 26293362
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypePartial Multi-year Fund
Section一般
Research Field Obstetrics and gynecology
Research InstitutionFukuoka University

Principal Investigator

Miyamoto Shingo  福岡大学, 医学部, 教授 (40209945)

Co-Investigator(Kenkyū-buntansha) 鍋島 一樹  福岡大学, 医学部, 教授 (40189189)
四元 房典  福岡大学, 医学部, 講師 (40533089)
八木 裕史  九州大学, 医学(系)研究科(研究院), 助教 (70623552)
Research Collaborator FUKAGAWA Satoshi  福岡大学, 医学部産婦人科学教室, 助教
Project Period (FY) 2014-04-01 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2016: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2014: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Keywords卵巣癌 / バイオマーカー / HB-EGF / BK-UM / miRNA / miR-135a-3p / microRNA / microRNA array / マイクロRNA / 診断マイクロアレイ
Outline of Final Research Achievements

Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis has remained extremely poor. In this study, to identify microRNAs involved in the progression of ovarian cancer we analyzed serum microRNAs in patients with ovarian cancer using microRNA array and qRT-PCR and examined the anticancer properties of microRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.

Report

(4 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Annual Research Report
  • 2014 Annual Research Report
  • Research Products

    (16 results)

All 2017 2016 2015 2014

All Journal Article (3 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 3 results,  Open Access: 3 results,  Acknowledgement Compliant: 1 results) Presentation (11 results) Patent(Industrial Property Rights) (2 results)

  • [Journal Article] BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.2017

    • Author(s)
      Miyamoto S, Yotsumoto F,他30名、 Iwamoto R, Mekada E.
    • Journal Title

      BMC Cancer.

      Volume: 17 Issue: 1 Pages: 89-97

    • DOI

      10.1186/s12885-017-3071-5

    • Related Report
      2016 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.2014

    • Author(s)
      Miyata K, Yotsumoto F, Nam SO, Odawara T, Manabe S, Ishikawa T, Itamochi H, Kigawa J, Takada S, Asahara H, Kuroki M, Miyamoto S
    • Journal Title

      Cancer Medicine

      Volume: 3 Issue: 5 Pages: 1159-1169

    • DOI

      10.1002/cam4.301

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.2014

    • Author(s)
      Nam SO, Yotsumoto F, Miyata K, Suzaki Y, Yagi H, Odawara T, Manabe S, Ishikawa T, Kuroki M, Mekada E, Miyamoto S
    • Journal Title

      Anticancer Research

      Volume: 34 Pages: 4615-4620

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Presentation] HB-EGF に関連した卵巣癌予後予測因子としての microRNA2016

    • Author(s)
      清島 千尋
    • Organizer
      第75回日本癌学会
    • Place of Presentation
      横浜
    • Year and Date
      2016-10-06
    • Related Report
      2016 Annual Research Report
  • [Presentation] 卵巣癌の予後を予測するmicroRNAの同定2016

    • Author(s)
      深川 怜史
    • Organizer
      第75回日本癌学会
    • Place of Presentation
      横浜
    • Year and Date
      2016-10-06
    • Related Report
      2016 Annual Research Report
  • [Presentation] 卵巣癌の予後予測因子としての microRNA-135a2016

    • Author(s)
      深川 怜史
    • Organizer
      第15回日本婦人科がん分子標的研究会
    • Place of Presentation
      札幌
    • Year and Date
      2016-08-19
    • Related Report
      2016 Annual Research Report
  • [Presentation] Identification of microRNA as a biomarker in primary ovarian cancer2016

    • Author(s)
      深川 怜史
    • Organizer
      第68回日本産科婦人科学会
    • Place of Presentation
      東京
    • Year and Date
      2016-04-21
    • Related Report
      2016 Annual Research Report
  • [Presentation] HB-EGF (Heparin Binding-Epidermal Growth Factor) に関連した卵巣癌予後予測2016

    • Author(s)
      清島 千尋
    • Organizer
      第68回日本産科婦人科学会
    • Place of Presentation
      東京
    • Year and Date
      2016-04-21
    • Related Report
      2016 Annual Research Report
  • [Presentation] 卵巣癌予後予測因子としての microRNA の解析2015

    • Author(s)
      深川怜史、宮田康平、四元房典、黒木政秀、安永晋一郎、宮本新吾
    • Organizer
      日本癌学会
    • Place of Presentation
      (名古屋)名古屋国際会議場
    • Year and Date
      2015-10-08
    • Related Report
      2015 Annual Research Report
  • [Presentation] 卵巣癌における予後予測および薬剤感受性に関わるmicroRNA2015

    • Author(s)
      四元房典、深川怜史、宮田康平、南 星旭、安永晋一郎、黒木政秀、宮本新吾
    • Organizer
      第14回日本婦人科がん分子標的研究会学術集会
    • Place of Presentation
      (松本) 美ケ原温泉ホテル翔峰
    • Year and Date
      2015-07-18
    • Related Report
      2015 Annual Research Report
  • [Presentation] 卵巣癌予後予測因子としてのmicroRNAの検索2015

    • Author(s)
      深川怜史、宮田康平、南星旭、四元房典、宮本新吾
    • Organizer
      第67回日本産婦人科学会学術集会
    • Place of Presentation
      (横浜)パシフィコ横浜
    • Year and Date
      2015-04-09
    • Related Report
      2015 Annual Research Report
  • [Presentation] 癌治療標的分子HB-EGFの翻訳制御にかかわる分子の同定2014

    • Author(s)
      宮田康平、四元房典、深川怜史、南星旭、黒木政秀、宮本新吾
    • Organizer
      第18回バイオ治療法研究会学術集会
    • Place of Presentation
      高松
    • Year and Date
      2014-12-13
    • Related Report
      2014 Annual Research Report
  • [Presentation] Antitumor effect of intravenous injection of an HB-EGF inhibitor, CRM197, in triple negative breast cancer2014

    • Author(s)
      Satoshi Fukagawa, Sung Ouk Nam, Fusanori Yotsumoto, Kohei Miyata, Masahide Kuroki, Shingo Miyamoto
    • Organizer
      第73回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Related Report
      2014 Annual Research Report
  • [Presentation] Regulation of HB-EGF expression via a translational regulator, RBM8A.2014

    • Author(s)
      Miyata K, Yotsumoto F, Nam SO, Fukagawa S, Kuroki M, Miyamoto S
    • Organizer
      第73回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Related Report
      2014 Annual Research Report
  • [Patent(Industrial Property Rights)] 卵巣癌の予後検査・診断方法2016

    • Inventor(s)
      宮本 新吾、宮田 康平
    • Industrial Property Rights Holder
      宮本 新吾、宮田 康平
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2015-080452
    • Filing Date
      2016-04-09
    • Related Report
      2016 Annual Research Report
  • [Patent(Industrial Property Rights)] 卵巣がんの予後検査・診断方法2016

    • Inventor(s)
      宮田 康平、宮本 新吾
    • Industrial Property Rights Holder
      宮田 康平、宮本 新吾
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2015-080452
    • Filing Date
      2016-04-09
    • Related Report
      2015 Annual Research Report

URL: 

Published: 2014-04-04   Modified: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi